Enhanced Systemic Antitumour Immunity by Hypofractionated Radiotherapy and Anti-PD-L1 Therapy in Dogs with Pulmonary Metastatic Oral Malignant Melanoma
Cancers · 01.06.2023 · 15 (11) · 3013
DOI: 10.3390/cancers15113013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 01.06.2023. Verfasst von Tatsuya Deguchi und 17 weiteren Autor:innen. Beteiligte Einrichtung: Veterinary Teaching Hospital, Faculty of Veterinary Medicine, Hokkaido University, Sapporo 060-0819, Japan. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research, Grant-in-Aid for JSPS Fellows.
Abstract (Originalsprache)
Although immune checkpoint inhibitors (ICIs), such as the anti-programmed death-ligand 1 (PD-L1) antibody, have been developed for the treatment of canine malignant melanoma, desirable clinical efficacies have not been achieved. Recent studies in humans have suggested that radiation therapy (RT) combined with ICIs induces robust systemic antitumour immunity in patients with cancer. This study retrospectively examined the therapeutic efficacy of combination therapy (hypofractionated RT and anti-PD-L1 antibody [c4G12]) in dogs with pulmonary metastatic oral malignant melanoma. The intrathoracic clinical benefit rate (CBR)/median overall survival (OS) in the no RT (n = 20, free from the effect of RT), previous RT (n = 9, received RT ≤8 weeks prior to the first c4G12 dose), and concurrent RT (n = 10, c4G12 therapy within ±1 week of the first RT fraction) groups were 10%/185 days, 55.6%/283.5 days (p < 0.05 vs. no RT group), and 20%/129 days (p > 0.05 vs. no RT group), respectively. The adverse events were considered to be tolerable in the combination therapy. Thus, hypofractionated RT before the initiation of c4G12 therapy can be an effective approach for enhancing the therapeutic efficacy of immunotherapy, with acceptable safety profiles. Further prospective clinical studies are required to confirm the findings of this study.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Veterinary Teaching Hospital, Faculty of Veterinary Medicine, Hokkaido University, Sapporo 060-0819, Japan.
- Department of Advanced Pharmaceutics, Faculty of Veterinary Medicine, Hokkaido University, Sapporo 060-0818, Japan.
- Department of Disease Control, Faculty of Veterinary Medicine, Hokkaido University, Sapporo 060-0818, Japan.
- Department of Veterinary Surgery 1, School of Veterinary Medicine, Azabu University, Sagamihara 252-5201, Japan.
- Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan.
- Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan.
ORCID-Profile: Keitaro Morishita, Tomohiro Okagawa, Yukinari Kato, Yasuhiko Suzuki, Shiro Murata
Förderung
- Japan Society for the Promotion of Science
- Grant-in-Aid for Scientific Research
- Grant-in-Aid for JSPS Fellows
- Japan Agency for Medical Research and Development (AMED)
Zitieren
APA
Deguchi, T., Maekawa, N., Konnai, S., Owaki, R., Hosoya, K., Morishita, K., Nakamura, M., Okagawa, T., Takeuchi, H., Kim, S., Kinoshita, R., Tachibana, Y., Yokokawa, M., Takagi, S., Kato, Y., Suzuki, Y., Murata, S., & Ohashi, K. (2023). Enhanced Systemic Antitumour Immunity by Hypofractionated Radiotherapy and Anti-PD-L1 Therapy in Dogs with Pulmonary Metastatic Oral Malignant Melanoma. Cancers, 15(11), 3013. https://doi.org/10.3390/cancers15113013
Vancouver
Deguchi T, Maekawa N, Konnai S, Owaki R, Hosoya K, Morishita K, et al. Enhanced Systemic Antitumour Immunity by Hypofractionated Radiotherapy and Anti-PD-L1 Therapy in Dogs with Pulmonary Metastatic Oral Malignant Melanoma. Cancers. 2023;15(11):3013. doi:10.3390/cancers15113013
BibTeX
@article{Deguchi2023,
author = {Deguchi, Tatsuya and Maekawa, Naoya and Konnai, Satoru and Owaki, Ryo and Hosoya, Kenji and Morishita, Keitaro and Nakamura, Motoji and Okagawa, Tomohiro and Takeuchi, Hiroto and Kim, Sangho and Kinoshita, Ryohei and Tachibana, Yurika and Yokokawa, Madoka and Takagi, Satoshi and Kato, Yukinari and Suzuki, Yasuhiko and Murata, Shiro and Ohashi, Kazuhiko},
title = {Enhanced Systemic Antitumour Immunity by Hypofractionated Radiotherapy and Anti-PD-L1 Therapy in Dogs with Pulmonary Metastatic Oral Malignant Melanoma},
journal = {Cancers},
year = {2023},
volume = {15},
number = {11},
pages = {3013},
doi = {10.3390/cancers15113013}
}
EUVIMED